Severin Schwan - Roche Holding CEO and Executive Director
| RHHBY Stock | USD 35.49 0.36 1.02% |
CEO
Dr. Severin Schwan was Chairman of the Corporationrationrate Executive Committee, Chief Executive Officer and Executive Director of Roche Holding Ltd since 2013. He was Chairman of the Corporationrationrate Executive Committee and Chief Executive Officer of Roche Holding AG from March 4, 2008. He was previously Chief Executive Officer of the Division Roche Diagnostics and Member of the Corporationrationrate Executive Committee at the Company from January 1, 2006. Between 1993 and 1995, he was a Trainee at Corporationrationrate Finance for Roche Basel. From 1995 until 1998, he was Head of Finance Administration at Roche Brussels. From 1998 until 2000, Dr. Schwan was Head Finance Informatics at Roche Grenzach, Germany and Member of the Executive Board of Roche Deutschland Holding GmbH. From 2000 until 2004, he was Head of Global Finance Services at Roche Diagnostics, Basel. Since 2009, Dr. Schwan was Member of the Board of Directors of Chugai Pharmaceuticals, Japan, and Member of the International Business Leaders Advisory Council for the Mayor of Shanghai . Dr. Schwan studied Economics at Universitaet Innsbruck, University of York and University of Oxford. He gained an Economics Degree from Innsbruck. He studied Law at Universitaet Innsbruck and gained a Law degree in 1991 since 2013.
| Age | 56 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | CEO Age | ||
| Deborah Waterhouse | GlaxoSmithKline PLC ADR | N/A | |
| Pascal Soriot | AstraZeneca PLC ADR | 60 | |
| Emma Walmsley | GlaxoSmithKline PLC ADR | 55 | |
| Brian McNamara | GlaxoSmithKline PLC ADR | 49 | |
| Richard Saynor | Novartis AG ADR | 57 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Barbara Schadler, Head Communications | ||
| Claudia Bockstiegel, G Counsel | ||
| Bruno Eschli, Head Relations | ||
| Johannes MD, Head Devel | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
| William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
| Alan Hippe, Chief Financial and IT Officer | ||
| Severin Schwan, CEO and Executive Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 293.22 B | |||
| Shares Outstanding | 6.4 B | |||
| Shares Owned By Institutions | 1.27 % | |||
| Price To Earning | 17.56 X | |||
| Price To Book | 9.81 X | |||
| Price To Sales | 3.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Roche OTC Stock Analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.